Quabodepistat

Synonym(s): OPC-167832

Class: 3,4-dihydrocarbostyril derivative

Details of activity:	Antimycobacterial activity against Mycobacterium tuberculosis
Institute where first reported:	Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan
Year first mentioned:	2020
Highest developmental phase:	Phase 2 (NCT05971602)
Development status:	Active

Chemical structure(s):
Canonical SMILES:	C1CC(=O)NC2=C1C(=CC=C2F)OC[C@@]3(CCN(C[C@H]3O)C4=C(C=C(C=C4F)Cl)F)O
Isomeric SMILES:	C1CC(=O)NC2=C(C=CC(=C21)OC[C@@]3(CCN(C[C@H]3O)C4=C(C=C(C=C4F)Cl)F)O)F
InChI:	InChI=1S/C21H20ClF3N2O4/c22-11-7-14(24)20(15(25)8-11)27-6-5-21(30,17(28)9-27)10-31-16-3-2-13(23)19-12(16)1-4-18(29)26-19/h2-3,7-8,17,28,30H,1,4-6,9-10H2,(H,26,29)/t17-,21-/m1/s1
InChI Key:	XZISSTDXPBUCJA-DYESRHJHSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/118904282

External links:
Guide to Pharmacology:	quabodepistat
Main Source:	https://aac.asm.org/content/64/6/e02020-19
Citation:	https://aac.asm.org/content/63/8/e00603-19